


EVERY LIFE COUNTS



A Committee of **CoNGO**



Why LYS SMAL is formed? ASSOCIATION



By TAN SHIOW CHIN

starhealth@thestar.com.my

N THE not-too-distant past, it was common for parents to pray for boys to carry on the family line.

Newadays, most parents just hope that their newborn child will be healthy, with all their fingers, toes and everything else in the right

And rightfully so, because there can be no harder blow than when a child is born with a defect or abnormality.

But it is far worse when the baby turns out. to have a rare disease, simply because of the difficulty in obtaining a diagnosis and treatment, as well as the general lack of knowledge about such conditions.

Two in the family

Engineer Lee Yee Seng, 37, and stay-at-home mum Chia Kian Foon, 41, have three children. The eldest, 11-year-old Yen Ling, and youngest, Wei Ling, 7, are girls, with the middle one is See Hong, a nine-year-old boy.

While Wei Ling was always a sickly child from birth, it wasn't until her first birthday that it dawned on her parents that there was something seriously wrong with her.

Says Chia: "At one year of age, Wei Ling was losing out on all the gross motor development.

"Normally, at one, kids can stand (with support), but she couldn't stand or even crawl. And she fell sick very easily, and it would drag. on for a long time."

In addition, she had very poor weight gain, despite a good appetite, and was prone to choking on food easily.

Around that time, she was also suffering. from a respiratory infection. As it had dragged on for almost two months without improvement, despite oral antibiotics, she was admitted to the Seremban General Hospital.

Upon taking a chest X-ray, it was discovered

A hard, lonely road

Two families share their experiences with rare diseases.



An energetic Sze Hong nurs ahead of (from left) Ven Ling, Lee, Wei Ling and Chia, as the family goes for a walk around the neighbourhood. He was fortunate enough to miss out on the genetic lottery that gove Nis sisters Pompe disease. - UU BAN/The Star



Chia holding the then 20-month-old Wei Ling, who has obviously weak muscle tone - a typical symptom of Pompe disease.



CoNGO The Conference of NGOs in Consultative Relationship with the United Nations













Before ERT

After ERT – Wei Ling life takes a quick u-turn...



2006

2007

2008

2011

The Miracle of MYOZYME



玮玲就医后获得重生











Before ERT

After ERT - Yen Ling life was back to normal...

2001

2003

2007

2008

2011

燕林过着平凡人的生活







1st MLDA Protemp Committee on April Fool 2011

Malaysia Lysosomal Disases Association (MLDA) was founded by 7 families.

Our Vision

To ensure that all patients who suffering from LSD receive proper medical treatment and enjoy equal opportunities in life regardless of race gender, age, education and religion.

Our Mission

- 1. Educate and incraese public awareness on the existence of LSD
- 2. Advocate and work with policy makers towards better support for LSD patients.
- 3. Support the welfare of LSD patient and their families.







Statistics

Patients Count

Ethnicity and Gender Distribution







ACTIVITIES HIGHLIGHT

❖ Ice Bucket Challenge Sep 2014 Subang Jaya









ACTIVITIES HIGHLIGHT

Every Life Counts Charity Dinner Empire Hotel 2016 Fund Raised 116k USD





ACTIVITIES HIGHLIGHT

RARE DISEASES

Provided 11 families with money allocation every 2 month.

()		Total	RM 2,960.00
11	Mohd Najmudin bin Yasok	Sunsidising	200.00
10	Jussena Ata Ak Jaboh	Sunsidising	360.00
9	Nur Nadia Bt Shamsudin	Sunsidising	200.00
8	Faizal bin Sait	Sunsidising	200.00
7	Sunarti binti Che Wil	Sunsidising	400.00
6	Norhaiwati binti Che Wil	Sunsidising	200.00
5	Bong Siaw Fui	Sunsidising	400.00
4	Paezah binti Awang Puteh	Sunsidising	200.00
3	Subaramaniam A/L Nagappan	Sunsidising	200.00
2	Salbiah binti Mohd. Razali	Sunsidising	400.00
1	Muhamad Shapingi bin Hashim	Sunsidising	200.00

RM 17,760 per year USD 4,200

PATIENT SUPPORT & CARE

MLDA procured 3 mini lpad, 5 sofa bed(USD 1100) and freezer +Data net (USD 4100) for Hospital Kuala Lumpur children.













International Collaboration



International Collaboration

Singapore 2012 – Asia Orphan Drug Congress

Osaka Japan 2013- international MPS Meeting

Bahiia Brazil, 2014 – International MPS Meeting







Singapore 2015 – First Asia Rare Disease Conference



Patient Advocacy Group Panel - Landscape of the Support Networks in Asia

Bonn, German 2016 – International MPS Meeting



Today



Next Week



17th Sep 2016





Every Life Counts Charity Dinner 2014 One City, USJ Fund Raised 163K USD



Every Life Counts Charity Dinner 2014 One City, Malaysia Health Minister granted us RM 2.5mil. We use 2 mil to procure drugs to save 7 life. Another 0.5 mil for genetic screening for MPS II



The King receives a gift of one of the members of MLDA



The Minister of Health welcomed by Haziq a MPS type 6 patient




Our Challenges



Statistics

Patient Treatment Status



TREATMENT ENDING by Jan 2017

No	Name of Patients	Age (years)	Location	Disease	ERT Treatment Status	Estimation Cost per Year	ERT Start Date	ERT End Date	Efficiency of ERT	Medication
1	Muhammad Hazim Imran Bin Faizal	11	Shah Alam, Selangor	MPS Type II Hunter	Ending by Apr 16	RM 994,500.00	15 Apr 2015	14 Apr 2016	- Finger less stiff - Appetite Improved - Taller	Elaprase or Hunterase
2	Liew May Yee @ Jooel	28	lpoh, Perak	GSD Type II Pompe	Ending by Apr 16	RM 1,000,480.00	16 Apr 2015	15 Apr 2016	- Able to walk around unaided - Neck is stronger - Able to stand up unaided	Myozyme
3	Maclean Korinth Anak Malken	7	Kuching, Sarawak	MPS Type II Hunter	Ending by Apr 16	RM 976,083.00	29 Apr 2015	28 Apr 2016	Able to walk up the staircase unaided Increased in immunity Improved in balancing	Elaprase or Hunterase
4	Afiq Luqman Bin Mad Nawi	12	Kelang, Selangor	MPS Type II Hunter	Ending by Jun 16	RM 979,766.00	2 Jun 2015	1 Jun 2016	- More active in sports and physical activities - Less snoring - Stomach no more swollen	Elaprase or Hunterase

TREATMENT ENDING by Jan 2017

No	Name of Patients	Age (years)	Location	Disease	ERT Treatment Status	Estimation Cost per Year	ERT Start Date	ERT End Date	Efficiency of ERT	Medication
5	Darmash A/L Subaramanlam	16	Mentakab, Pahang	MPS Type II Hunter	Ending by Aug 16	RM 913,466.00	6 Aug 2015	5 Aug 2016	- Stomach no more swollen - Fingers less stiff - Facial features have soften	Elaprase or Hunterase
6	Lim Wei-Jann	7	Puchong, Selangor	MPS Type II Hunter	Ending by Sep 16	RM 1,042,383.00	23 Sep 2015	22 Sep 2016	- Stomach no more swollen - Fingers less stiff - Facial features have soften - Able to waik up the staircase unaided - More verbal	Elaprase or Hunterase
7	Muhammad Shafwan Bin Mohd Salim	8	Tanah Merah, Kelantan	MPS Type II Hunter	Ending by Mar 17	RM 699,833.00	1 Apr 2016	31 Mar 2017	- Just started	Elaprase or Hunterase
						RM 6,606,511.00				

In memorial of Darmash





STILL WAITING FOR TREATMENT

No	Name of Patients	Age (years)	Location	Disease	ERT Treatment Status	Waiting Period	Estimation Cost per Year	ERT Start Date	ERT End Date	Efficiency of ERT	Medication
W 1	Aaron Ng Yik Fung	4	Ampang, KL	MPS Type VI Maroteaux- Lamy	Waiting	2 years	RM 842,400.00	-	,	-	Naglazyme
W 2	Adnin Bt Baharudin	16	Subang Jaya, Selangor	MPS Type IVA Morquio	Waiting	2 years	RM 1,347,840.00	-	,	-	Vimizim
W 3	Ahmad Adam Bin Sharin	7	Petaling Jaya, Selangor	MPS Type II Hunter	Waiting	2 years	RM 773,500.00				Elaprase or Hunterase
W 4	Aqilah Bt Baharudin	14	Subang Jaya, Selangor	MPS Type IVA Morquio	Waiting	2 years	RM 1,198,080.00		-	-	Vimizim

STILL WAITING FOR TREATMENT

No	Name of Patients	Age (years)	Location	Disease	ERT Treatment Status	Waiting Period	Estimation Cost per Year	ERT Start Date	ERT End Date	Efficiency of ERT	Medication
W 5	Muhammad Arman Bin Sharin	3	Petaling Jaya, Selangor	MPS Type II Hunter	Waiting	2 years	RM 552,500.00	-	-	-	Elaprase or Hunterase
W 6	Siti Nur Shahira Bt Muhd Nizam	12	Rawang, Selangor	MPS Type IVA Morquio	Waiting	2 years	RM 1,123,200.00	-	-	-	Vimizim
W 7	Woon Jia Huey	17	Cheras, KL	MPS Type IVA Morquio	Waiting	2 years	RM 1,572,480.00	-	-	-	Vimizim
8 8	A male patient	23	lpoh, Perak	Pompe	Waiting	3 years	RM 811,200.00				
						Total:	RM 8,221,200.00				
G						Grand Total:	RM 14,827,711.00				

RESEARCH Open Access



State of rare disease management in Southeast Asia

Asrul Akmal Shafie^{1*}, Nathorn Chaiyakunapruk^{2,3,4,5}, Azuwana Supian¹, Jeremy Lim⁶, Matt Zafra⁶ and Mohamed Azmi Ahmad Hassali¹



Fig. 1 Rare disease journey-Progress of SEA and benchmark countries

Table 1 National initiatives to support rare diseases and access to orphan drugs

	Indicator	Philippines	Singapore	Malaysia	Indonesia	Vietnam	Thailand
Health system	GDP per capita (USD)	2,588	54,007	10,440	3,551	1,755	5,480
	Health expenditure per capita (USD)	119	2,426	410	108	103	215
	Total health expenditure (% of GDP)	4.6	4.7	39	3.0	6.6	3.9
	Health coverage (%) [37]	76	100	100	48	55	98
	Out of pocket health expenditure (% of total expenditure on health)	52.0	58.6	35.6	45.3	48.8	13.1
	Life expectancy at birth (years) [40]	69	82	75	70	73	75
	Mortality rate, infant (per 1,000 live births) [40]	22	1.8	7	32	16	11
Governance	Presence of national strategy	Yes	No	In progress	No	No	No
	Definition of rare disease	Yes	Yes	Yes	No	No	No
	Comprehensive rare disease legislation	Yes (2015)	No	No	No	No	No
	Orphan drug act/ legislation	Pending approval	Yes (1991)	No	No	No	No
Awareness	Patient support/advocacy groups	PSOD	RDSS	MLDS, MMA, MRDS	No	NPH RD club	Genetic LSD Foundation
	Patient support group activity	Yes (since 2010)	Yes (since 2013)	Yes (since 2010)	No	Yes (since 2013)	Yes (since 2011)
	Media attention (Based on Factiva search from 2009–2015)	72 articles	48 articles	33 articles	13 articles	26 articles	12 articles
Clinical	Presence of patient registries	Largely institution specific			No	No	Planned, LSD diseases
expertise	Presence of centre of expertise	Yes (1)	Yes (2)	Yes (3)	No	Yes (1)	Yes (2)
	Presence of national guidelines for treatment	No	No	No	No	No	No
	Professional societies to support specialist	No	No	Limited	No	No	No
Funding	Government funding for rare disease treatments	Limited	Limited	Limited	No	No	Limited
	Government funding for rare disease research	No	Yes	No	No	No	No
	Non-government access to rare disease treatment	Some charitable and industry funds	Some charitable and industry funds	Some charitable and industry funds, employer benefits	No	No	Some charitable and industry funds
New born	National reonatal screening programs	Yes	Yes	Yes	No	Yes	Yes
screening	Percentage of new born screened	28 %	100 %	>95 %	<1.96	31 %	>97 %
	Source of payment for the new born screening	OOP/insurance	OOP (40 %)	Gov./OOP	OOP	Government	

Abbreviations: OOP Out of Pocket, Gov Government, PSOD Philippine Society for Orphan Disorders, RDSS Rare Disorders Society (Singapore), MLDA Malaysia Lysosomal Diseases Association, MMA Malaysian Medical Association, MRDS Malaysian Rare Disorders Society, NPH RD National Pediatric Hospital (rare disease), LSD Lysosomal storage diseases







A Committee of **CoNGO**






"I have a dream".....

- * Firstly: To formulate an International Policy to protect the right for rare disease patients across the globe.
- * 2nd: To mark Rare Disease as one of the key issue in UN meeting.
- * 3rd: UN Economic & Social Council to file up any discrimination cases in certain countries when the code of ethic has been violated.
- * 4th: UN to help collaborate medical assessment in countries with unmet medical needs. Help governing and regulate orphan drug pricing to avoid overpricing that could deprive of the chance for treatment.



15,106 km

Distance from Kuala Lumpur to United Nations Headquarters



To fight for the children is a long journey
Until we get to know about ConNGO
You are the light at the end of the tunnel for us
Today is a beautiful day because

Love travel 15,106KM away and unite us together Let's not leave anyone behind...



Thank You So Much!

